How much funding has Imara raised?

Imara has raised $94.0M in total funding, most recently a Series B round.

Who are Imara's investors?

Imara's investors include OrbiMed, Arix Bioscience, New Enterprise Associates, Rock Springs Capital, Alexandria Venture Investments, Pfizer Ventures.

Where is Imara headquartered?

Imara is headquartered in Boston, Massachusetts, United States.

What industry is Imara in?

Imara operates in Biotech, Healthcare.

Imara

IPO

Public · Boston, United States · Founded 2016 · $94.0M raised

Biotech

Healthcare

Headquarters: Boston, Massachusetts
Employees: 11–50
Founded: 2016
Business Model: B2B
Website: imarainc.com

Total Funding: $94.0M
Last Round: $63.0M Series BMar 2019
Rounds: 2
Type: Public

About

Imara Inc. was a Boston-based clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for sickle cell disease and beta-thalassemia. Founded in 2016, Imara advanced its lead candidate tovinontrine through clinical trials before discontinuing the program in 2022. The company subsequently completed a reverse merger with Enliven Therapeutics in February 2023.

Summary

Imara is a Biotech company based in Boston, United States, founded in 2016. It has raised $94.0M in total across 2 rounds, most recently a $63.0M Series B round in Mar 2019. Investors include OrbiMed, Arix Bioscience and New Enterprise Associates.